​

Novavax (NVAX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NVAX Stock Forecast

Novavax (NVAX) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $14.50, with a high of $18.00 and a low of $11.00. This represents a 66.67% increase from the last price of $8.70.

- $4 $8 $12 $16 $20 High: $18 Avg: $14.5 Low: $11 Last Closed Price: $8.7

NVAX Stock Rating

Novavax stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (72.73%), 3 Hold (13.64%), 3 Sell (13.64%), and 0 Strong Sell (0.00%).

Buy
Total 22 3 3 16 0 Strong Sell Sell Hold Buy Strong Buy

NVAX Price Target Upside V Benchmarks

TypeNameUpside
StockNovavax66.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts223
Avg Price Target$14.50$14.50$17.00
Last Closing Price$8.70$8.70$8.70
Upside/Downside66.67%66.67%95.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25131128
Sep, 25131128
Aug, 25-32117
Jul, 25-32117
Jun, 25-32-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2025Cantor Fitzgerald$18.00$8.55110.53%106.90%
Oct 23, 2025Sean LeeH.C. Wainwright$11.00$8.4630.02%26.44%
Nov 18, 2024Mayank MamtaniB.Riley Financial$22.00$7.58190.24%152.87%
Oct 16, 2024Roger SongJefferies$25.00$10.15146.31%187.36%
Oct 16, 2024Alec StranahanBank of America Securities$14.00$10.4533.97%60.92%
Jul 19, 2024Roger SongJefferies$31.00$14.36115.88%256.32%
May 10, 2024Vernon BernardinoH.C. Wainwright$19.00$9.9491.15%118.39%
Feb 14, 2022Charles DuncanCantor Fitzgerald$174.00$80.11117.20%1900.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2025Cantor FitzgeraldOverweightOverweightinitialise
Oct 23, 2025H.C. WainwrightBuyBuyhold
Jun 17, 2025CitigroupSellinitialise
May 19, 2025B. RileyBuyBuyhold
Feb 27, 2025BTIGBuyinitialise
Nov 13, 2024H.C. WainwrightBuyBuyhold
Oct 16, 2024JefferiesBuyBuyhold
Oct 16, 2024Bank of America SecuritiesNeutralNeutralhold
Oct 10, 2024B. RileyBuyBuyhold
Jul 19, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-19 $-13 $-7 $-1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.43$-23.44$-8.42$-5.41$-1.23----
Avg Forecast$-5.81$-13.70$-7.16$-4.22$-1.28$0.13$0.96$1.57$1.10
High Forecast$-3.92$-9.24$-3.77$-3.38$-0.77$2.73$1.48$1.73$2.37
Low Forecast$-9.02$-21.28$-12.31$-5.14$-1.56$-1.91$0.13$1.41$0.27
Surprise %27.88%71.09%17.60%28.20%-3.91%----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$475.60M$1.15B$1.60B$556.38M$682.16M----
Avg Forecast$446.35M$1.26B$2.01B$1.01B$724.07M$557.33M$652.01M$530.45M$594.90M
High Forecast$636.32M$1.80B$3.12B$1.05B$1.37B$1.07B$1.23B$1.00B$1.12B
Low Forecast$334.67M$947.15M$1.28B$978.85M$302.16M$237.41M$272.09M$221.36M$248.25M
Surprise %6.55%-9.26%-20.36%-45.15%-5.79%----

Net Income Forecast

$-7B $-5B $-4B $-2B $-900M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-427.50M$-1.74B$-657.94M$-545.06M$-187.50M----
Avg Forecast$-585.13M$-4.02B$-5.11B$-545.06M$-117.20M$81.66M$80.95M$158.21M$110.84M
High Forecast$-394.80M$-3.22B$-4.00B$-426.64M$-77.48M$275.38M$148.85M$174.18M$238.60M
Low Forecast$-908.87M$-4.83B$-6.22B$-663.49M$-156.92M$-192.77M$13.06M$142.23M$26.88M
Surprise %-26.94%-56.67%-87.13%-59.98%----

NVAX Forecast FAQ

Is Novavax stock a buy?

Novavax stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 3 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Novavax is a favorable investment for most analysts.

What is Novavax's price target?

Novavax's price target, set by 22 Wall Street analysts, averages $14.5 over the next 12 months. The price target range spans from $11 at the low end to $18 at the high end, suggesting a potential 66.67% change from the previous closing price of $8.7.

How does Novavax stock forecast compare to its benchmarks?

Novavax's stock forecast shows a 66.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Novavax over the past three months?

  • October 2025: 12.50% Strong Buy, 37.50% Buy, 12.50% Hold, 12.50% Sell, 25.00% Strong Sell.
  • September 2025: 12.50% Strong Buy, 37.50% Buy, 12.50% Hold, 12.50% Sell, 25.00% Strong Sell.
  • August 2025: 0% Strong Buy, 42.86% Buy, 28.57% Hold, 14.29% Sell, 14.29% Strong Sell.

What is Novavax’s EPS forecast?

Novavax's average annual EPS forecast for its fiscal year ending in December 2025 is $0.13, marking a -110.57% decrease from the reported $-1.23 in 2024. Estimates for the following years are $0.96 in 2026, $1.57 in 2027, and $1.1 in 2028.

What is Novavax’s revenue forecast?

Novavax's average annual revenue forecast for its fiscal year ending in December 2025 is $557.33M, reflecting a -18.30% decrease from the reported $682.16M in 2024. The forecast for 2026 is $652.01M, followed by $530.45M for 2027, and $594.9M for 2028.

What is Novavax’s net income forecast?

Novavax's net income forecast for the fiscal year ending in December 2025 stands at $81.66M, representing a -143.55% decrease from the reported $-187M in 2024. Projections indicate $80.95M in 2026, $158.21M in 2027, and $110.84M in 2028.